Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders

26-04-2024 | Insulins | Research article

The glucose tolerance peak parameter revisited. Definition for a novel use in Gestational Diabetes Mellitus confirmation

Author: Myriam Ben Abdelhanin

Published in: Journal of Diabetes & Metabolic Disorders

Login to get access

Abstract

Aims

This study aimed to establish a decisive threshold for the Glucose Tolerance peak (GTp) parameter in diagnosing Gestational Diabetes Mellitus (GDM) and to assess its diagnostic efficacy in comparison with other commonly employed indexes in clinical practice.

Materials and methods

Conducted as a prospective observational cohort, the study enrolled 92 pregnant women between 24–28 weeks of gestation, who underwent an Oral glucose Tolerance Test (OGTT) 100 gr. following a positive O'Sullivan screening at La Paz University Hospital. An additional 30-min sample was incorporated to assess the insulin response dynamics during hyperglycaemia. Basal indices and those derived from the OGTT 100 gr. test were computed. Receiver Operating Characteristic (ROC) curves were utilized to determine the optimal cut-off points for the indexes derived from the OGTT. Informed written consent was obtained from all participants.

Results

Significantly greater glucose tolerance, as indicated by GTp, was observed in the Non-Gestational Diabetes (NTG) pregnant group (p < 0.01). The GTp emerged as the parameter with the highest positive predictive value for GDM diagnosis. A cut-off of < 0.36 demonstrated 100% specificity and 75% sensitivity in diagnosing GDM.

Conclusions

GTp, an index derived exclusively from the OGTT peak glycaemia, proves valuable in confirming the presence of GDM. The GTp could be used to confirm the presence of GDM under necessity of a second OGTT as test confirmation in pregnant woman. A cut-off of < 0. 36 has a specificity of 100% and a sensitivity of 75% for the diagnosis of GDM.
Literature
1.
Sluiter WJ, Erkelens DW, Terpstra P, Reitsma WD, Doorenbos H. Glucose Tolerance and Insulin Release. A Mathematical approach: II. approximation of the peripheral insulin resistance after oral glucose loading. Diabetes. 1976;25(4):245–9.CrossRefPubMed
2.
3.
Nolfe G, Spreghini MR, Wietrzycowska Sforza R, Morino G, Manco M. Beyond the morphology of the glucose curve following an oral glucose tolerance test in obese youth. Eur J Endocrinol. 2012;166(1):107–14.CrossRefPubMed
4.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMed
5.
Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–10.CrossRefPubMed
6.
Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med. 1994;11(3):286–92.CrossRefPubMed
7.
8.
Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.CrossRefPubMed
9.
Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care. 2007;30(1):89–94.CrossRefPubMed
10.
Kramer CK, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R. Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum. Diabetologia. 2015;58:1354–62.CrossRefPubMed
11.
Chung ST, Ha J, Onuzuruike AU, Kasturi K, Galvan-De La Cruz M, Bingham BA, Baker RL, Utumatwishima JN, Mabundo LS, Ricks M, Sherman AS, Sumner AE. Time to glucose peak during an oral glucose tolerance test identifies prediabetes risk. Clin Endocrinol (Oxf) 2017;87:484–91.
12.
Abdul-Ghani MA, Lyssenko V, Tuomi T, Defronzo RA, Groop L. The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab Res Rev. 2010;26(4):280–6.CrossRefPubMed
13.
Olefsky J, Reaven GM, Farquhar JW. Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest. 1974;53(1):64–76.CrossRefPubMedPubMedCentral
14.
Zimmet PZ, Wall JR, Rome R, Stimmler L, Jarrett RJ. Diurnal variation in glucose tolerance: associated changes in plasma insulin, growth hormone, and non-esterified fatty acids. Br Med J. 1974;1(5906):485–8.CrossRefPubMedPubMedCentral
15.
Grupo Español de Diabetes y Embarazo. Asistencia a la gestante con diabetes. Guía de práctica clínica actualizada en 2014. Av Diabetol. 2015;31(2):45–59.
16.
Metadata
Title
The glucose tolerance peak parameter revisited. Definition for a novel use in Gestational Diabetes Mellitus confirmation
Author
Myriam Ben Abdelhanin
Publication date
26-04-2024
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-024-01432-4
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits